Aprea Therapeutics: Latest News, Top Stories & Analysis - Page 3 of 3

DOYLESTOWN, PA — Aprea Therapeutics (Nasdaq: APRE) has announced a key update in its ongoing Phase 1/2a ABOYA-119 clinical trial for ATRN-119, aimed at treating advanced solid tumors with DNA damage …

Regional

Aprea Therapeutics Reports Q3 Financials and Advances in Clinical Trials

November 9, 2024November 8, 2024 - by Timothy Alexander

DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) released its third-quarter financial results for 2024, reporting key advancements in its clinical-stage therapeutic candidates. The company is making significant strides in …